Functional reconstitution of human neuropeptide y (NPY) Y 2 and Y 4 receptors in Sf9 insect cells

Journal of Receptors and Signal Transduction

Volumn 31, Issue 4, 2011, Pages 271-285

  Pop, Nathalie ^a   Igel, Patrick ^a   Brennauer, Albert ^a   Cabrele, Chiara ^b   Bernhardt, Günther ^a   Seifert, Roland ^c   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Gi G o proteins; Neuropeptide Y Y 2 receptor; Neuropeptide Y Y 4 receptor; RGS protein; Sf9 insect cells; Steady state GTPase assay

Indexed keywords

BW 1911U90; G PROTEIN COUPLED RECEPTOR; GR 231118; GUANIDINE DERIVATIVE; GUANOSINE TRIPHOSPHATASE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; PERTUSSIS TOXIN; RECEPTOR SUBTYPE; TUNICAMYCIN; UNCLASSIFIED DRUG; URP 1284;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; GENETIC ENGINEERING; GLYCOSYLATION; IMMUNOBLOTTING; INSECT CELL; LIGAND BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; STEADY STATE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; HUMANS; INSECTS; LIGANDS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEUROPEPTIDE Y; RATS; RECEPTORS, NEUROPEPTIDE Y; SALTS; SWINE;

HEXAPODA;

EID: 79960328914     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2011.583253     Document Type: Article

References (87)

1. Merten N, Beck-Sickinger AG. Molecular ligand-receptor interaction of the NPY/PP peptide family. EXS 2006, 35-62.
2. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998, 50, 143-150. (Pubitemid 28158845)
3. Gehlert DR. Neuropeptide Y (NP Y) and its receptors. In: Squire LR, editor. Encyclopedia of Neuroscience 2009. La Jolla, CA: Academic Press, 2009, pp. 837-842.
4. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci 2003, 60, 350-377. (Pubitemid 36343914)
5. 1, Y2, or Y5 receptors. Obes Res 2005, 13, 36-47.
6. Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol 2001, 60, 534-540. (Pubitemid 32781561)
7. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl- Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171. (Pubitemid 26242883)
8. Mashiko S, Ishihara A, Iwaasa H, Sano H, Oda Z, Ito J, Yumoto M, Okawa M, Suzuki J, Fukuroda T, Jitsuoka M, Morin NR, MacNeil DJ, Van der Ploeg LH, Ihara M, Fukami T, Kanatani A. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology 2003, 144, 1793-1801. (Pubitemid 36543317)
9. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418, 650-654.
10. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003, 124, 1325-1336. (Pubitemid 36531807)
11. Sato N, Ogino Y, Mashiko S, Ando M. Modulation of neuropeptide Y receptors for the treatment of obesity. Expert Opin Ther Pat 2009, 19, 1401-1415.
12. Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thone-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschop M. PYY3-36 as an anti-obesity drug target. Obes Rev 2005, 6, 307-322. (Pubitemid 41578600)
13. 2receptor antagonists discovered by whole-cell high-throughput screening. Mol Pharmacol 2010, 77, 46-57.
14. Shoblock JR, Welty N, Nepomuceno D, Lord B, Aluisio L, Fraser I, Motley ST, Sutton SW, Morton K, Galici R, Atack JR, Dvorak L, Swanson DM, Carruthers NI, Dvorak C, Lovenberg TW, Bonaventure P. In vitro and in vivo characterization of JNJ- 31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl] piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. Psychopharmacology (Berl) 2010, 208, 265-277.
15. 4 receptor by flow cytometry and aequorin luminescence. J Recept Signal Transduct Res 2007, 27, 217-233. (Pubitemid 47450772)
16. Bischoff A, Puttmann K, Kotting A, Moser C, Buschauer A, Michel MC. Limited signal transduction repertoire of human Y(5) neuropeptide Y receptors expressed in HEC-1B cells. Peptides 2001, 22, 387-394. (Pubitemid 32250239)
17. Dautzenberg FM, Higelin J, Pflieger P, Neidhart W, Guba W. Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoylthiazol- 2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist. Neuropharmacology 2005, 48, 1043-1055. (Pubitemid 40602612)
18. 2receptor subtype. J Biol Chem 1995, 270, 26758-26761.
19. Lundell I, Blomqvist AG, Berglund MM, Schober DA, Johnson D, Statnick MA, Gadski RA, Gehlert DR, Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem 1995, 270, 29123-29128.
20. 4 receptor agonists. Eur J Pharmacol 1998, 349, 97-105. (Pubitemid 28270662)
21. Dumont Y, Cadieux A, Doods H, Pheng LH, Abounader R, Hamel E, Jacques D, Regoli D, Quirion R. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol 2000, 129, 1075-1088. (Pubitemid 30153963)
22. Merten N, Lindner D, Rabe N, Rompler H, Morl K, Schoneberg T, Beck-Sickinger AG. Receptor subtype-specific docking of Asp6.59 with C-terminal arginine residues in Y receptor ligands. J Biol Chem 2007, 282, 7543-7551. (Pubitemid 47093642)
23. Berridge MJ. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. Biochem J 1983, 212, 849-858. (Pubitemid 13056904)
24. 2receptor ligands. Eur J Pharmacol 2006, 551, 10-18. (Pubitemid 44648057)
25. Schneider EH, Seifert R. Sf9 cells: a versatile model system to investigate the pharmacological properties of G protein-coupled receptors. Pharmacol Ther 2010, 128, 387-418.
26. Wieland T, Seifert R. Methodological approaches. In: Seifert R, Wieland T, editors. G-Protein Coupled Receptors as Drug Targets (Methods and Principles in Medicinal Chemistry). Weinheim, Germany: Wiley-VCH, 2005, pp. 81-120.
27. Massotte D. G protein-coupled receptor overexpression with the baculovirus-insect cell system: a tool for structural and functional studies. Biochim Biophys Acta 2003, 1610, 77-89. (Pubitemid 36173999)
28. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450, 383-387. (Pubitemid 350126755)
29. Quehenberger O, Prossnitz ER, Cochrane CG, Ye RD. Absence of G(i) proteins in the Sf9 insect cell. Characterization of the uncoupled recombinant N-formyl peptide receptor. J Biol Chem 1992, 267, 19757-19760.
30. Mulheron JG, Casanas SJ, Arthur JM, Garnovskaya MN, Gettys TW, Raymond JR. Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s). J Biol Chem 1994, 269, 12954-12962.
31. Parker EM, Kameyama K, Higashijima T, Ross EM. Reconstitutively active G protein-coupled receptors purified from baculovirusinfected insect cells. J Biol Chem 1991, 266, 519-527. (Pubitemid 21906154)
32. 1 neuropeptide Y receptor expressed in insect cells. Mol Cell Endocrinol 1995, 107, 77-86.
33. Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8- tetrahydro-9-isopropyl-carbazol- 3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J Pharmacol Exp Ther 2006, 317, 562-570.
34. Block MH, Boyer S, Brailsford W, Brittain DR, Carroll D, Chapman S, Clarke DS, Donald CS, Foote KM, Godfrey L, Ladner A, Marsham PR, Masters DJ, Mee CD, ODonovan MR, Pease JE, Pickup AG, Rayner JW, Roberts A, Schofield P, Suleman A, Turnbull AV. Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J Med Chem 2002, 45, 3509-3523. (Pubitemid 34824039)
35. Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, Spaltenstein A. High-affinity neuropeptide Y receptor antagonists. Proc Natl Acad Sci USA 1995, 92, 9067-9071.
36. Cabrele C, Wieland HA, Langer M, Stidsen CE, Beck-Sickinger AG. Y-receptor affinity modulation by the design of pancreatic polypeptide/ neuropeptide Y chimera led to Y(5)-receptor ligands with picomolar affinity. Peptides 2001, 22, 365-378. (Pubitemid 32250237)
37. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 1999, 384, R3-R5. (Pubitemid 30006963)
38. Dollinger H, Esser F, Mihm G, Rudolf K, Schnorrenberg G, Gaida W, Doods HN, inventors; Boehringer Ingelheim Pharma, assignee. Preparation of novel peptides for use as NPY antagonists. Ger Offen patent DE 19816929, 1999.
39. 2receptor antagonists: synthesis, stability and pharmacological activity [Thesis]. Regensburg, Germany: University of Regensburg, 2006.
40. Walseth TF, Johnson RA. The enzymatic preparation of [alpha-(32) P]nucleoside triphosphates, cyclic [32P] AMP, and cyclic [32P] GMP. Biochim Biophys Acta 1979, 562, 11-31.
41. Seifert R, Lee TW, Lam VT, Kobilka BK. Reconstitution of beta2- adrenoceptor-GTP-binding-protein interaction in Sf9 cells-high coupling efficiency in a beta2-adrenoceptor-G(s alpha) fusion protein. Eur J Biochem 1998, 255, 369-382. (Pubitemid 28340245)
42. Wenzel-Seifert K, Seifert R. Critical role of N-terminal N-glycosylation for proper folding of the human formyl peptide receptor. Biochem Biophys Res Commun 2003, 301, 693-698. (Pubitemid 36277662)
43. Kleemann P, Papa D, Vigil-Cruz S, Seifert R. Functional reconstitution of the human chemokine receptor CXCR4 with G(i)/G(o)-proteins in Sf9 insect cells. Naunyn Schmiedebergs Arch Pharmacol 2008, 378, 261-274.
44. Preuss H, Ghorai P, Kraus A, Dove S, Buschauer A, Seifert R. Constitutive activity and ligand selectivity of human, guinea pig, rat, and canine histamine H2 receptors. J Pharmacol Exp Ther 2007, 321, 983-995. (Pubitemid 46762691)
45. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22, 3099-3108.
46. 4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 1995, 270, 26762-26765.
47. 2receptor. J Biol Chem 1995, 270, 18523-18530.
48. 4 receptor: resistance to agonist-promoted desensitization. J Pharmacol Exp Ther 2000, 292, 638-646. (Pubitemid 30067427)
49. Fabre C, el Battari A, Karamanos Y, Couvineau A, Salomon R, Laburthe M, Marvaldi J, Pichon J, Luis J. Glycosylation of VIP receptors: a molecular basis for receptor heterogeneity. Peptides 1993, 14, 483-489.
50. Grunewald S, Haase W, Reilander H, Michel H. Glycosylation, palmitoylation, and localization of the human D2S receptor in baculovirus-infected insect cells. Biochemistry 1996, 35, 15149-15161. (Pubitemid 26408846)
51. Seifert R, Wenzel-Seifert K. Defective Gi protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodontitis. J Biol Chem 2001, 276, 42043-42049.
52. Seifert R, Wenzel-Seifert K, Burckstummer T, Pertz HH, Schunack W, Dove S, Buschauer A, Elz S. Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther 2003, 305, 1104-1115. (Pubitemid 36617989)
53. Sternweis PC, Robishaw JD. Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J Biol Chem 1984, 259, 13806-13813. (Pubitemid 15224957)
54. Seifert R, Wenzel-Seifert K. Unmasking different constitutive activity of four chemoattractant receptors using Na+ as universal stabilizer of the inactive (R) state. Recept Channels 2001, 7, 357-369. (Pubitemid 32970634)
55. Seifert R, Wenzel-Seifert K. Constitutive activity of G-proteincoupled receptors: cause of disease and common property of wildtype receptors. Naunyn Schmiedebergs Arch Pharmacol 2002, 366, 381-416. (Pubitemid 35251788)
56. Schnell D, Seifert R. Modulation of histamine H(3) receptor function by monovalent ions. Neurosci Lett 2010, 472, 114-118.
57. Gille A, Seifert R. Co-expression of the beta2-adrenoceptor and dopamine D1-receptor with Gs alpha proteins in Sf9 insect cells: limitations in comparison with fusion proteins. Biochim Biophys Acta 2003, 1613, 101-114. (Pubitemid 36776513)
58. Schnell D, Burleigh K, Trick J, Seifert R. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers. J Pharmacol Exp Ther 2010, 332, 996-1005.
59. 2receptors by co-expression of chimeric G proteins. Biochem Pharmacol 2005, 69, 1493-1499. (Pubitemid 40602449)
60. 4 receptors for pancreatic polypeptide. Peptides 1997, 18, 609-612. (Pubitemid 127739667)
61. Cox HM, Tough IR, Zandvliet DW, Holliday ND. Constitutive neuropeptide Y Y(4) receptor expression in human colonic adenocarcinoma cell lines. Br J Pharmacol 2001, 132, 345-353. (Pubitemid 32128466)
62. 4 receptor [Thesis]. Regensburg, Germany: University of Regensburg, 2006.
63. Schneider EH, Schnell D, Papa D, Seifert R. High constitutive activity and a G-protein-independent high-affinity state of the human histamine H(4)-receptor. Biochemistry 2009, 48, 1424-1438.
64. Kelley LP, Kinsella BT. The role of N-linked glycosylation in determining the surface expression, G protein interaction and effector coupling of the alpha (alpha) isoform of the human thromboxane A(2) receptor. Biochim Biophys Acta 2003, 1621, 192-203. (Pubitemid 36515099)
65. Zhou H, Tai HH. Characterization of recombinant human CXCR4 in insect cells: role of extracellular domains and N-glycosylation in ligand binding. Arch Biochem Biophys 1999, 369, 267-276. (Pubitemid 29455607)
66. Yurugi-Kobayashi T, Asada H, Shiroishi M, Shimamura T, Funamoto S, Katsuta N, Ito K, Sugawara T, Tokuda N, Tsujimoto H, Murata T, Nomura N, Haga K, Haga T, Iwata S, Kobayashi T. Comparison of functional non-glycosylated GPCRs expression in Pichia pastoris. Biochem Biophys Res Commun 2009, 380, 271-276.
67. 4 receptors in smooth muscle coupled to distinct signaling pathways. J Pharmacol Exp Ther 2004, 311, 1154-1162. (Pubitemid 39612723)
68. Birnbaumer L, Abramowitz J, Brown AM. Receptor-effector coupling by G proteins. Biochim Biophys Acta 1990, 1031, 163-224.
69. Schneider EH, Seifert R. Histamine H(4) receptor-RGS fusion proteins expressed in Sf9 insect cells: a sensitive and reliable approach for the functional characterization of histamine H(4) receptor ligands. Biochem Pharmacol 2009, 78, 607-616.
70. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ, Kenakin T. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 2000, 57, 125-134. (Pubitemid 30033268)
71. Wenzel-Seifert K, Hurt CM, Seifert R. High constitutive activity of the human formyl peptide receptor. J Biol Chem 1998, 273, 24181-24189. (Pubitemid 28435765)
72. Parker MS, Lundell I, Parker SL. Pancreatic polypeptide receptors: affinity, sodium sensitivity and stability of agonist binding. Peptides 2002, 23, 291-303. (Pubitemid 34127967)
73. Higashijima T, Ferguson KM, Sternweis PC. Regulation of hormonesensitive GTP-dependent regulatory proteins by chloride. J Biol Chem 1987, 262, 3597-3602.
74. Seifert R. Monovalent anions differentially modulate coupling of the beta2-adrenoceptor to G(s)alpha splice variants. J Pharmacol Exp Ther 2001, 298, 840-847. (Pubitemid 32674118)
75. Lindner D, Stichel J, Beck-Sickinger AG. Molecular recognition of the NPY hormone family by their receptors. Nutrition 2008, 24, 907-917.
76. Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR. The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction. J Pharmacol Exp Ther 2003, 306, 147-156. (Pubitemid 36734368)
77. 4 receptor homodimers dissociate upon agonist stimulation. J Pharmacol Exp Ther 2003, 307, 1120-1126. (Pubitemid 37494232)
78. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001, 15, 598-611. (Pubitemid 32245978)
79. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 2007, 72, 1393-1401. (Pubitemid 350146075)
80. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011, 336, 296-302.
81. Neubig RR. Missing links: mechanisms of protean agonism. Mol Pharmacol 2007, 71, 1200-1202. (Pubitemid 46658671)
82. Perez DM, Karnik SS. Multiple signaling states of G-proteincoupled receptors. Pharmacol Rev 2005, 57, 147-161. (Pubitemid 41043881)
83. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 2010, 62, 305-330.
84. 2receptor. Eur J Biochem 2001, 268, 877-886. (Pubitemid 32328331)
85. Bohme I, Stichel J, Walther C, Morl K, Beck-Sickinger AG. Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus. Cell Signal 2008, 20, 1740-1749.
86. Jozwiak K, Khalid C, Tanga MJ, Berzetei-Gurske I, Jimenez L, Kozocas JA, Woo A, Zhu W, Xiao RP, Abernethy DR, Wainer IW. Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem 2007, 50, 2903-2915. (Pubitemid 46980861)
87. Rosethorne EM, Charlton SJ. Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits beta-arrestin without activating G proteins. Mol Pharmacol 2011, 79, 749-757.